Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | SC |
Wrong route of administration; This non-serious case was reported by a other health professional via call center representative and described the occurrence of intramuscular formulation administered by other route in a 71-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. On 05-FEB-2025, the patient received the 1st dose of Shingrix (subcutaneous). On 05-FEB-2025, an unknown time after receiving Shingrix, the patient experienced intramuscular formulation administered by other route (Verbatim: Wrong route of administration). The outcome of the intramuscular formulation administered by other route was not applicable. Additional Information: GSK Receipt Date: 27-MAR-2025 The healthcare professional explained that a patient received their first dose of Shingrix on 5th February 2025, but it was given subcutaneously instead of intramuscular which led to intramuscular formulation administered by other route.